AR054123A1 - Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato - Google Patents
Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolatoInfo
- Publication number
- AR054123A1 AR054123A1 ARP060101915A ARP060101915A AR054123A1 AR 054123 A1 AR054123 A1 AR 054123A1 AR P060101915 A ARP060101915 A AR P060101915A AR P060101915 A ARP060101915 A AR P060101915A AR 054123 A1 AR054123 A1 AR 054123A1
- Authority
- AR
- Argentina
- Prior art keywords
- folate
- methyl
- deficiencies
- pharmaceutical composition
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Composicion farmacéutica que contiene gestágenos, preferiblemente drospirenona, estrogenos, preferiblemente etinilestradiol y 5-metil-(6S)-tetrahidrofolato, que puede ser usada como anticonceptivo oral y también previene enfermedades provocadas por carencias de folato de las consumidoras, especialmente enfermedades cardio-circulatorias y después de la concepcion del embrion, malformaciones congénitas por carencias de folato, como por ejemplo, defectos del tubo neural, defectos de las válvulas ventriculares, malformaciones urogenitales y hendiduras de labios, mandíbula y paladar, sin enmascarar los síntomas de una carencia de vitamina B12, y en el caso de existir un polimorfismo homo o heterocigota de la metilentetrahidrofolato-reductasa, al mismo tiempo favorece la utilizacion ilimitada del componente de folato de 5-metil-(6S)-tetrahidrofolato por el organismo, y con ello su actividad biologica, para evitar las malformaciones congénitas provocadas por carencias de folato mencionadas previamente. Además, se mantiene un efecto protector prolongado después de interrumpir el uso del anticonceptivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005023301A DE102005023301B4 (de) | 2005-05-13 | 2005-05-13 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
DE102006016285A DE102006016285A1 (de) | 2006-04-03 | 2006-04-03 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054123A1 true AR054123A1 (es) | 2007-06-06 |
Family
ID=37396913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101915A AR054123A1 (es) | 2005-05-13 | 2006-05-12 | Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato |
Country Status (38)
Country | Link |
---|---|
US (2) | US20080160004A1 (es) |
EP (3) | EP2116249B2 (es) |
JP (2) | JP2008540482A (es) |
KR (2) | KR20080028369A (es) |
CN (2) | CN101954083A (es) |
AR (1) | AR054123A1 (es) |
AT (2) | ATE429917T1 (es) |
AU (1) | AU2006245921A1 (es) |
BR (1) | BRPI0611443B8 (es) |
CA (1) | CA2608639C (es) |
CL (2) | CL2009002187A1 (es) |
CR (1) | CR9531A (es) |
CY (2) | CY1109261T1 (es) |
DE (1) | DE502006003617D1 (es) |
DK (2) | DK1888077T3 (es) |
DO (1) | DOP2006000110A (es) |
EA (2) | EA028530B1 (es) |
EC (1) | ECSP078001A (es) |
ES (2) | ES2325600T3 (es) |
GT (1) | GT200600200A (es) |
HK (1) | HK1118729A1 (es) |
HR (1) | HRP20090418T1 (es) |
IL (1) | IL187340A (es) |
MA (1) | MA29448B1 (es) |
MY (1) | MY147362A (es) |
NO (1) | NO345807B1 (es) |
PE (1) | PE20061415A1 (es) |
PL (2) | PL1888077T3 (es) |
PT (2) | PT1888077E (es) |
RS (2) | RS50972B (es) |
SG (1) | SG169973A1 (es) |
SI (2) | SI2116249T1 (es) |
SV (1) | SV2008002527A (es) |
TN (1) | TNSN07418A1 (es) |
TW (1) | TWI380820B (es) |
UY (1) | UY29527A1 (es) |
WO (1) | WO2006120035A2 (es) |
ZA (1) | ZA200710811B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
JP2009542588A (ja) * | 2006-07-06 | 2009-12-03 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 避妊及び先天的異常の危険性の予防のための医薬製剤 |
EP1891959A1 (de) * | 2006-08-14 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
CN101674837A (zh) * | 2007-04-05 | 2010-03-17 | 拜耳先灵医药股份有限公司 | 新的屈螺酮/17β-***给药方案、用于实施该给药方案的药物组合产品和药盒 |
JP2011507853A (ja) * | 2007-12-20 | 2011-03-10 | テバ ウィメンズ ヘルス インコーポレイテッド | 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ |
TW200946542A (en) * | 2008-03-10 | 2009-11-16 | Vladimir Hanes | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
TW200942242A (en) * | 2008-03-10 | 2009-10-16 | Rolf Schurmann | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
MX356702B (es) | 2010-04-15 | 2018-06-11 | Bayer Ip Gmbh | Formas de dosificación sólidas orales con dosis muy bajas para la hrt. |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
EP2617422A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
EP2781214A1 (en) | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) |
CN104490887A (zh) * | 2014-09-04 | 2015-04-08 | 连云港金康和信药业有限公司 | (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物 |
RS62844B1 (sr) | 2015-06-18 | 2022-02-28 | Estetra Srl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
JP6866561B2 (ja) | 2015-06-18 | 2021-04-28 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | エステトロールを含有する口腔内崩壊錠 |
CA2988498C (en) | 2015-06-18 | 2022-02-08 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
CN106336444A (zh) * | 2016-08-23 | 2017-01-18 | 国家卫生计生委科学技术研究所 | 一种新晶型炔雌醇 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK174724B1 (da) * | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
US6083528A (en) * | 1995-09-28 | 2000-07-04 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
EP0857020A4 (en) * | 1995-10-27 | 1999-01-07 | Merck & Co Inc | FORMULATION OF SECRETAGOGUE STIMULATING THE SECRETION OF THE GROWTH HORMONE, INTENDED TO BE GRANULATED BY WET |
AU722050B2 (en) | 1996-01-31 | 2000-07-20 | South Alabama Medical Science Foundation | Food and vitamin preparations containing the natural isomer of reduced folates |
CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
ID24568A (id) * | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
CA2522761C (en) * | 1998-04-17 | 2010-07-06 | Michael E. Kafrissen | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
US7014865B1 (en) | 1998-10-19 | 2006-03-21 | Merck Patent Gmbh | Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid |
JP2002527484A (ja) * | 1998-10-19 | 2002-08-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤 |
CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
HU225779B1 (en) | 1999-07-28 | 2007-08-28 | Chinoin Gyogyszer Es Vegyeszet | Pharmaceutical composition containing paracetamol and drotaverine and process for producing it |
US6787531B1 (en) | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
KR101019361B1 (ko) | 1999-08-31 | 2011-03-07 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합 |
US6479545B1 (en) | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
DE10022510A1 (de) * | 2000-05-10 | 2001-11-15 | Basf Ag | Zusammensetzungen enthaltend Folsäure und reduziertes Folat |
EP1349554A2 (en) * | 2000-12-14 | 2003-10-08 | Tufts University | Compositions and methods for treating an arthritic condition |
US20030045510A1 (en) * | 2000-12-15 | 2003-03-06 | Schloss Caroline Maxine | Estrogen-plus |
EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
US20040220118A1 (en) * | 2001-02-02 | 2004-11-04 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
US20060034954A1 (en) * | 2001-02-02 | 2006-02-16 | Bland Jeffrey S | Medical composition for balancing bodily processes |
NZ534806A (en) * | 2002-02-21 | 2006-05-26 | Schering Ag | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin B12 |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
-
2006
- 2006-05-11 UY UY29527A patent/UY29527A1/es not_active Application Discontinuation
- 2006-05-12 PE PE2006000504A patent/PE20061415A1/es active IP Right Grant
- 2006-05-12 GT GT200600200A patent/GT200600200A/es unknown
- 2006-05-12 TW TW095116905A patent/TWI380820B/zh active
- 2006-05-12 SV SV2006002527A patent/SV2008002527A/es active IP Right Grant
- 2006-05-12 DO DO2006000110A patent/DOP2006000110A/es unknown
- 2006-05-12 AR ARP060101915A patent/AR054123A1/es not_active Application Discontinuation
- 2006-05-15 JP JP2008510518A patent/JP2008540482A/ja not_active Withdrawn
- 2006-05-15 SI SI200631375T patent/SI2116249T1/sl unknown
- 2006-05-15 WO PCT/EP2006/004858 patent/WO2006120035A2/de active Application Filing
- 2006-05-15 DK DK06753787T patent/DK1888077T3/da active
- 2006-05-15 KR KR1020077029090A patent/KR20080028369A/ko active Application Filing
- 2006-05-15 SI SI200630360T patent/SI1888077T1/sl unknown
- 2006-05-15 AT AT06753787T patent/ATE429917T1/de active
- 2006-05-15 AU AU2006245921A patent/AU2006245921A1/en not_active Abandoned
- 2006-05-15 SG SG201007499-5A patent/SG169973A1/en unknown
- 2006-05-15 PT PT06753787T patent/PT1888077E/pt unknown
- 2006-05-15 PL PL06753787T patent/PL1888077T3/pl unknown
- 2006-05-15 EP EP09075120.7A patent/EP2116249B2/de active Active
- 2006-05-15 AT AT09075120T patent/ATE555791T1/de active
- 2006-05-15 RS RSP-2009/0327A patent/RS50972B/sr unknown
- 2006-05-15 CA CA2608639A patent/CA2608639C/en not_active Expired - Fee Related
- 2006-05-15 ES ES06753787T patent/ES2325600T3/es active Active
- 2006-05-15 CN CN2010101564516A patent/CN101954083A/zh active Pending
- 2006-05-15 EA EA200901393A patent/EA028530B1/ru not_active IP Right Cessation
- 2006-05-15 NO NO20076408A patent/NO345807B1/no unknown
- 2006-05-15 EP EP10185658A patent/EP2298307A1/de not_active Withdrawn
- 2006-05-15 MY MYPI20062228A patent/MY147362A/en unknown
- 2006-05-15 EP EP06753787A patent/EP1888077B1/de active Active
- 2006-05-15 EA EA200702349A patent/EA014664B1/ru active Protection Beyond IP Right Term
- 2006-05-15 RS RS20120325A patent/RS52651B/en unknown
- 2006-05-15 BR BRPI0611443A patent/BRPI0611443B8/pt active IP Right Grant
- 2006-05-15 KR KR1020147010192A patent/KR101598735B1/ko active IP Right Grant
- 2006-05-15 DK DK09075120.7T patent/DK2116249T3/da active
- 2006-05-15 DE DE502006003617T patent/DE502006003617D1/de active Active
- 2006-05-15 PT PT09075120T patent/PT2116249E/pt unknown
- 2006-05-15 PL PL09075120T patent/PL2116249T3/pl unknown
- 2006-05-15 CN CN2006800164109A patent/CN101198332B/zh active Active
- 2006-05-15 ES ES09075120T patent/ES2387525T3/es active Active
-
2007
- 2007-11-12 TN TNP2007000418A patent/TNSN07418A1/en unknown
- 2007-11-12 US US11/938,688 patent/US20080160004A1/en not_active Abandoned
- 2007-11-13 IL IL187340A patent/IL187340A/en active IP Right Grant
- 2007-11-13 MA MA30367A patent/MA29448B1/fr unknown
- 2007-11-16 CR CR9531A patent/CR9531A/es not_active Application Discontinuation
- 2007-12-11 EC EC2007008001A patent/ECSP078001A/es unknown
- 2007-12-12 ZA ZA2007/10811A patent/ZA200710811B/en unknown
-
2008
- 2008-11-18 HK HK08112590.1A patent/HK1118729A1/xx unknown
-
2009
- 2009-07-27 HR HR20090418T patent/HRP20090418T1/xx unknown
- 2009-07-28 CY CY20091100804T patent/CY1109261T1/el unknown
- 2009-12-18 CL CL2009002187A patent/CL2009002187A1/es unknown
-
2010
- 2010-09-21 CL CL2010000989A patent/CL2010000989A1/es unknown
-
2012
- 2012-08-02 CY CY20121100689T patent/CY1114403T1/el unknown
-
2013
- 2013-02-18 JP JP2013029277A patent/JP5883810B2/ja active Active
-
2015
- 2015-12-10 US US14/965,173 patent/US10463666B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054123A1 (es) | Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
AR106561A2 (es) | Composición farmacéutica que contiene un ácido tetrahidrofólico | |
AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
CR10838A (es) | Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis | |
CL2007001961A1 (es) | Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo. | |
AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
DOP2011000304A (es) | Nuevos derivados de compuestos de [3,2-c] pirazol esteroidal con actividad glucocorticoide | |
AR095691A1 (es) | FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO | |
ECSP088472A (es) | Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento | |
CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
PE20090805A1 (es) | COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL | |
CU20070252A7 (es) | Composición farmacéutica que contiene drospirenona, etinilestradiol y la sal de calcio del ácido 5-metil-(6s)-tetrahidrofólico | |
UA92491C2 (ru) | Фармацевтическая композиция, которая содержит гестагены и/или эстрогены и 5-метил-(6s)-тетрагидрофолат | |
NZ737002A (en) | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate | |
CL2007002765A1 (es) | Formulacion farmaceutica que comprende un complejo de hidroxipropil-beta-ciclodextrina-progesterona, carboximetilquitosano, celulosa microcristalina y opcionalmente estearato de magnesio; procedimiento de preparacion; y uso para tratar desordenes ginecologicos. | |
DOP2007000117A (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal | ||
FB | Suspension of granting procedure | ||
FC | Refusal |